Blazing Star Merger Sub completes Walgreens debt tender offer
Investing.com - H.C. Wainwright has reiterated a Buy rating and $17.00 price target on Brainsway (NASDAQ:BWAY), the $288 million market cap medical device company that has delivered an impressive 61% return year-to-date. According to InvestingPro data, the company has shown strong momentum, trading near its 52-week high following the announcement of two strategic investments.
Brainsway reported last week that it entered into a strategic equity financing agreement with Axis Management Company, Inc., a management services organization servicing mental health clinics in Colorado. The deal involves an initial $2.3 million investment with a potential additional $1 million milestone-based investment for a minority position in Axis.
The company also closed an initial strategic investment through a $5 million convertible loan to Neurolief Ltd., with an option to acquire the company. Neurolief develops a wearable, non-invasive, multi-channel brain neuromodulation platform designed for home use, with technology showing positive clinical outcomes for treatment-resistant major depressive disorder and migraine.
H.C. Wainwright noted that while these arrangements involve different companies, both add value to Brainsway - Axis through potential revenue acceleration via the MSO portal, and Neurolief by expanding Brainsway’s technology offerings beyond Deep TMS.
With $78.3 million in cash as of mid-2025, H.C. Wainwright believes Brainsway is well-capitalized to make such investments, supporting the firm’s maintained Buy rating and 12-month price target of $17 per share.
In other recent news, BrainsWay Ltd. reported record quarterly net revenue of $12.6 million for Q2 2025, along with net earnings of $0.05 per share. The company shipped 88 Deep TMS systems during the quarter, marking a 35% increase compared to the same period last year, which expanded its total installed base to 1,522 systems. H.C. Wainwright responded by raising its price target for BrainsWay to $17 from $16, maintaining a Buy rating. In strategic investment developments, BrainsWay has made a $5 million convertible loan investment in Neurolief Ltd., with an option to acquire the company and additional milestone-based funding. This investment is part of BrainsWay’s strategy to enter the market for at-home mental health therapies. Additionally, BrainsWay announced a strategic equity financing agreement with Axis Management Company, investing $2.3 million initially, with a potential additional $1 million based on milestones. This investment secures a minority position in Axis through a preferred, annually compounding security. These moves highlight BrainsWay’s commitment to expanding its presence in mental health care solutions outside traditional clinical settings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.